Mechanisms of resistance to cisplatin and carboplatin

Critical Reviews in Oncology/Hematology

Volumn 63, Issue 1, 2007, Pages 12-31

  Stewart, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carboplatin; Cisplatin; Resistance

Indexed keywords

APOPTOSIS INHIBITOR; CADHERIN; CARBOPLATIN; CATENIN; CHECKPOINT KINASE 2; CISPLATIN; CYCLOOXYGENASE 2; HEAT SHOCK PROTEIN; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PLATINUM; PROTEIN KINASE C; TRANSCRIPTION FACTOR;

CANCER CHEMOTHERAPY; CELL CYCLE; CELL KILLING; COLON CANCER; DNA REPAIR; DOSE RESPONSE; DRUG BINDING; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG UPTAKE; HUMAN; KIDNEY CANCER; LUNG CANCER; MISMATCH REPAIR; REVIEW; TESTIS CARCINOMA; TUMOR BLOOD FLOW;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 34249321653     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.02.001     Document Type: Review

References (346)

1. McKeage M.J. Comparative adverse effect profiles of platinum drugs. Drug Saf 13 (1995) 228-244
2. Crawford D.R., and Davies K.J. Adaptive response and oxidative stress. Environ Health Perspect 102 Suppl 10 (1994) 25-28
3. Prestera T., Zhang Y., Spencer S.R., Wilczak C.A., and Talalay P. The electrophile counterattack response: protection against neoplasia and toxicity. Adv Enzyme Regul 33 (1993) 281-296
4. Soti C., and Csermely P. Pharmacological modulation of the heat shock response. Handb Exp Pharmacol (2006) 417-436
5. Goldie J.H., and Coldman A.J. A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses. Cancer Invest 3 (1985) 553-564
6. Stewart D.J., Tomiak E., Shamji F.M., Maziak D.E., and MacLeod P. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44 (2004) 241-249
7. Nyce J.W. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 386 (1997) 153-161
8. Graham C.H., Kobayashi H., Stankiewicz K.S., Man S., Kapitain S.J., and Kerbel R.S. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst 86 (1994) 975-982
9. Di Nicolantonio F., Mercer S.J., Knight L.A., et al. Cancer cell adaptation to chemotherapy. BMC Cancer 5 (2005) 78
10. Akita H., Doki Y., Miyata H., et al. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol 93 (2006) 401-409
11. Stewart D.J., Raaphorst G.P., Yau J., and Beaubien A.R. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 14 (1996) 115-130
12. Stewart D., Chiritescu G., Dahrouge S., Banerjee S., and Tomiak E. Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 33 (2007) 101-137
13. Mellor H.R., Ferguson D.J., and Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer 93 (2005) 302-309
14. Chekhun V.F., Lukyanova N.Y., Urchenko O.V., and Kulik G.I. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp Oncol 27 (2005) 191-195
15. Chau Q., and Stewart D.J. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant. Cancer Chemother Pharmacol 44 (1999) 193-202
16. Naumov G.N., Townson J.L., MacDonald I.C., et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 82 (2003) 199-206
17. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41 (1981) 73-81
18. Mapleson W.W. An electric analogue for uptake and exchange of inert gases and other agents. J Appl Physiol 18 (1963) 197-204
19. Bischoff K.B. Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep 59 (1975) 777-793
20. Lutz R.J., Galbraith W.M., Dedrick R.L., Shrager R., and Mellett L.B. A model for the kinetics of distribution of actinomycin-D in the beagle dog. J Pharmacol Exp Ther 200 (1977) 469-478
21. Stewart D.J., Molepo J.M., Green R.M., et al. Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 71 (1995) 598-604
22. Stewart D.J., Benjamin R.S., Luna M., et al. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10 (1982) 51-54
23. Stewart D, Molepo M, Mikhael N, Montpetit V, Goel R. Factors associated with tumor cisplatin content. In: Proc Am Assoc Cancer Res Abstract 39: Abstract # 2236; 1998.
24. Suzuki M., Hori K., Abe I., Saito S., and Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67 (1981) 663-669
25. Noguchi S., Miyauchi K., Nishizawa Y., et al. Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma. Cancer 62 (1988) 467-473
26. Guichard M., Lespinasse F., Trotter M., Durand R., and Chaplin D. The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts. Radiother Oncol 20 (1991) 117-123
27. Leonhardt H., and Grigoleit H.G. Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn Schmiedebergs Arch Pharmacol 299 (1977) 197-200
28. von Tempelhoff G.F., Heilmann L., Hommel G., and Pollow K. Impact of rheological variables in cancer. Semin Thromb Hemost 29 (2003) 499-513
29. Muizelaar J.P., Wei E.P., Kontos H.A., and Becker D.P. Mannitol causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes. J Neurosurg 59 (1983) 822-828
30. Andrews R.J., Bringas J.R., and Muto R.P. Effects of mannitol on cerebral blood flow, blood pressure, blood viscosity, hematocrit, sodium, and potassium. Surg Neurol 39 (1993) 218-222
31. Lowe G.D. Defibrinating agents: effects on blood rheology, blood flow and vascular diseases in controlled studies. Bibl Haematol (1981) 247-251
32. Boucher Y., Baxter L.T., and Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50 (1990) 4478-4484
33. Jain R.K. Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol 60 (1991) 85-100
34. Nathan S.S., DiResta G.R., Casas-Ganem J.E., et al. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11 (2005) 2389-2397
35. Berube M., Talbot M., Collin C., et al. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin. Int J Oncol 26 (2005) 405-413
36. Pompella A., De Tata V., Paolicchi A., and Zunino F. Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol 71 (2006) 231-238
37. Raghunand N., and Gillies R.J. pH and drug resistance in tumors. Drug Resist Updat 3 (2000) 39-47
38. Prescott D.M., Charles H.C., Poulson J.M., et al. The relationship between intracellular and extracellular pH in spontaneous canine tumors. Clin Cancer Res 6 (2000) 2501-2505
39. Laurencot C.M., and Kennedy K.A. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells. Oncol Res 7 (1995) 371-379
40. Raghunand N., He X., van Sluis R., et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80 (1999) 1005-1011
41. Kozin S.V., Shkarin P., and Gerweck L.E. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 61 (2001) 4740-4743
42. Dickson J.A., and Calderwood S.K. Effects of hyperglycemia and hyperthermia on the pH, glycolysis, and respiration of the Yoshida sarcoma in vivo. J Natl Cancer Inst 63 (1979) 1371-1381
43. Andrews P., Mann S., Velury S., and Howell S. Cisplatin uptake mediated cisplatin-resistance in human ovarian carcinoma cells. In: Nicolini M. (Ed). Platinum and other metal coordination compounds in cancer chemotherapy (1988), Martinus Nijhoff Publishing, Boston, MA 248-254
44. Stewart D.J., Grewaal D., Popovic P., et al. Effect of cations on cisplatin uptake and efficacy in lung cancer cell lines. Proc Am Assoc Cancer Res 36 (1995) 399
45. Takahashi K., Seki T., Nishikawa K., et al. Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin. Jpn J Cancer Res 76 (1985) 68-74
46. Melvik J.E., Dornish J.M., and Pettersen E.O. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. Br J Cancer 66 (1992) 260-265
47. Fracasso M.E., Apostoli P., Benoni G., Bonetti A., Griso C., and Leone R. Kinetics of platinum in cancer patients treated with cisplatin at different doses. Drugs Exp Clin Res 13 (1987) 367-372
48. Vermorken J.B., van der Vijgh W.J., Klein I., Hart A.A., Gall H.E., and Pinedo H.M. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68 (1984) 505-513
49. Perera A., Jackson H., Sharma H.L., McAuliffe C.A., and Fox B.W. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro). Chem Biol Interact 85 (1992) 199-213
50. van der Vijgh W.J. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21 (1991) 242-261
51. Gaver R.C., George A.M., and Deeb G. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin. Cancer Chemother Pharmacol 20 (1987) 271-276
52. Johnson S.W., Shen D., Pastan I., Gottesman M.M., and Hamilton T.C. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res 226 (1996) 133-139
53. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
54. Andrews P.A., Velury S., Mann S.C., and Howell S.B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48 (1988) 68-73
55. Stewart D.J., Grewaal D., Molepo J.M., Popovic P., and Goel R. Effect of metabolic inhibitors and cations on cisplatin efflux from lung cancer cell lines. Proc Am Assoc Cancer Res 37 (1996) 174
56. Mann S.C., Andrews P.A., and Howell S.B. Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res 8 (1988) 1211-1215
57. Popovic P., Wong P., Goel R., Evans W.K., Howell S.B., and Stewart D.J. Pressure-tuning infrared spectra of cisplatin sensitive and resistant human ovarian cancer cells exposed to cisplatin. Proc Am Assoc Cancer Res 34 (1993) 404
58. Popovic P., Wong P.T.T., Kates M., et al. Membrane fluidity and lipids in cisplatin resistant cells with low cisplatin uptake. Proc Am Assoc Cancer Res 35 (1994) 440
59. Min J., Stegner A.L., Alexander H., and Alexander S. Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in Dictyostelium discoideum results in a selective increase in sensitivity to platinum-based chemotherapy drugs. Eukaryot Cell 3 (2004) 795-805
60. Upadhyay A.K., Singh S., Chhipa R.R., Vijayakumar M.V., Ajay A.K., and Bhat M.K. Methyl-beta-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and Bcl-2. Toxicol Appl Pharmacol 216 (2006) 177-185
61. Kiura K., Watarai S., Ueoka H., et al. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line. Anticancer Res 18 (1998) 2957-2960
62. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53 (2005) 13-23
63. Ishida S., Lee J., Thiele D.J., and Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99 (2002) 14298-14302
64. Safaei R., Katano K., Samimi G., et al. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53 (2004) 239-246
65. Lin X., Okuda T., Holzer A., and Howell S.B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62 (2002) 1154-1159
66. Holzer A.K., Katano K., Klomp L.W., and Howell S.B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10 (2004) 6744-6749
67. Shen D.W., Su A., Liang X.J., Pai-Panandiker A., and Gottesman M.M. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer 91 (2004) 270-276
68. Liang X.J., Mukherjee S., Shen D.W., Maxfield F.R., and Gottesman M.M. Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res 66 (2006) 2346-2353
69. Mann S.C., Andrews P.A., and Howell S.B. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25 (1990) 236-240
70. Wang W., Ke S., Chen G., et al. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Oncol Rep 12 (2004) 1365-1370
71. Nakayama K., Miyazaki K., Kanzaki A., Fukumoto M., and Takebayashi Y. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 8 (2001) 1285-1287
72. Katano K., Safaei R., Samimi G., Holzer A., Rochdi M., and Howell S.B. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64 (2003) 466-473
73. Higashimoto M., Kanzaki A., Shimakawa T., et al. Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma. Int J Mol Med 11 (2003) 337-341
74. Miyashita H., Nitta Y., Mori S., et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncol 39 (2003) 157-162
75. Safaei R., Larson B.J., Cheng T.C., et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4 (2005) 1595-1604
76. Samimi G., Safaei R., Katano K., et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10 (2004) 4661-4669
77. Ishikawa T., Wright C.D., and Ishizuka H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 269 (1994) 29085-29093
78. Taniguchi K., Wada M., Kohno K., et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56 (1996) 4124-4129
79. Kobayashi T., Fujii T., Jo Y., Kinugawa K., and Fujisawa M. Possible mechanism responsible for the acquisition of resistance to cis-diamminedichloroplatinum (II) by cultured human testicular seminoma cells. J Urol 171 (2004) 1929-1933
80. Nakamura M., Nakatani K., Uzawa K., et al. Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line H-1R. Oncol Rep 14 (2005) 1281-1286
81. Materna V., Liedert B., Thomale J., and Lage H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 115 (2005) 393-402
82. Peng Z.M., Luo J., Wang W.B., Wang X.H., Chen J.H., and Lan S.M. Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III. Ai Zheng 23 (2004) 963-967
83. Saikawa Y., Sugiura T., Toriumi F., et al. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res 24 (2004) 2723-2728
84. Yeh J.J., Hsu N.Y., Hsu W.H., Tsai C.H., Lin C.C., and Liang J.A. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 183 (2005) 177-183
85. Monden N., Abe S., Hishikawa Y., et al. The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy. Int J Surg Investig 1 (1999) 3-10
86. Zhang T., Guan M., Jin H.Y., and Lu Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol Oncol 97 (2005) 501-507
87. Xu H., Choi S.M., An C.S., et al. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 328 (2005) 618-622
88. Berger W., Elbling L., and Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 88 (2000) 293-300
89. Ikeda K., Oka M., Narasaki F., et al. Lung resistance-related protein gene expression and drug sensitivity in human gastric and lung cancer cells. Anticancer Res 18 (1998) 3077-3080
90. Zurita A.J., Diestra J.E., Condom E., et al. Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer 88 (2003) 879-886
91. Ikuta K., Takemura K., Sasaki K., et al. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 28 (2005) 707-712
92. Guminski A.D., Balleine R.L., Chiew Y.E., et al. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 100 (2006) 239-246
93. Pastan I., Gottesman M.M., Ueda K., Lovelace E., Rutherford A.V., and Willingham M.C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85 (1988) 4486-4490
94. Chen K.G., Valencia J.C., Lai B., et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 103 (2006) 9903-9907
95. Andersson A., Hedenmalm H., Elfsson B., and Ehrsson H. Determination of the acid dissociation constant for cis-diammineaquachloroplatinum(II) ion. A hydrolysis product of cisplatin. J Pharm Sci 83 (1994) 859-862
96. Perego P., Romanelli S., Carenini N., et al. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol 9 (1998) 423-430
97. Masters J.R., Thomas R., Hall A.G., et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 32A (1996) 1248-1253
98. Fokkema E., Groen H.J., Helder M.N., de Vries E.G., and Meijer C. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63 (2002) 1989-1996
99. Bose Girigoswami K., Bhaumik G., and Ghosh R. Induced resistance in cells exposed to repeated low doses of H2O2 involves enhanced activity of antioxidant enzymes. Cell Biol Int 29 (2005) 761-767
100. Byun S.S., Kim S.W., Choi H., Lee C., and Lee E. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 95 (2005) 1086-1090
101. Medeiros R., Pereira D., Afonso N., et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8 (2003) 156-161
102. Richardson M.E., and Siemann D.W. Thiol-related mechanisms of resistance in a murine tumor model. Int J Radiat Oncol Biol Phys 29 (1994) 387-392
103. Cao W., Zuo J., and Fang F. Role of glutathione S-transferase pi in tumor drug resistance. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 21 (1999) 402-406
104. Cullen K.J., Newkirk K.A., Schumaker L.M., Aldosari N., Rone J.D., and Haddad B.R. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63 (2003) 8097-8102
105. Kase H., Kodama S., Nagai E., and Tanaka K. Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Acta Cytol 42 (1998) 1397-1402
106. Cabelguenne A., Loriot M.A., Stucker I., et al. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 93 (2001) 725-730
107. Ryu J.S., Hong Y.C., Han H.S., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44 (2004) 311-316
108. Surowiak P., Materna V., Kaplenko I., et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 447 (2005) 626-633
109. Kimura S., Imagawa Y., Satake K., and Tsukuda M. The relationship of the human glutathione S-transferase P1 polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma. Int J Mol Med 14 (2004) 185-189
110. Nishi M., Abe Y., Fujimori S., et al. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo. Oncol Rep 14 (2005) 421-424
111. Rosell R., Cobo M., Isla D., et al. Applications of genomics in NSCLC. Lung Cancer 50 Suppl 2 (2005) S33-S40
112. Altaha R., Liang X., Yu J.J., and Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14 (2004) 959-970
113. Taron M., Rosell R., Felip E., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13 (2004) 2443-2449
114. Chen Y.J., Yuan C.C., Chow K.C., et al. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol 97 (2005) 110-117
115. Ebadi M., and Iversen P.L. Metallothionein in carcinogenesis and cancer chemotherapy. Gen Pharmacol 25 (1994) 1297-1310
116. Andrews P.A., Murphy M.P., and Howell S.B. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 19 (1987) 149-154
117. Endo T., Yoshikawa M., Ebara M., et al. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 39 (2004) 1196-1201
118. Huang P.Y., Liang X.M., Lin S.X., Luo R.Z., Hou J.H., and Zhang L. Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Ai Zheng 23 (2004) 845-850
119. Smith D.J., Jaggi M., Zhang W., et al. Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology 67 (2006) 1341-1347
120. Davies M.S., Berners-Price S.J., and Hambley T.W. Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg Chem 39 (2000) 5603-5613
121. Zwelling L.A., and Kohn K.W. Mechanism of action of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 63 (1979) 1439-1444
122. Poirier M.C., Egorin M.J., Fichtinger-Schepman A.M., Yuspa S.H., and Reed E. DNA adducts of cisplatin and carboplatin in tissues of cancer patients (1988), IARC Sci Publ. pp. 313-20
123. Reed E., Ozols R.F., Tarone R., Yuspa S.H., and Poirier M.C. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 84 (1987) 5024-5028
124. Reed E., Ostchega Y., Steinberg S.M., et al. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50 (1990) 2256-2260
125. Parker R.J., Gill I., Tarone R., et al. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 12 (1991) 1253-1258
126. Dabholkar M., Bradshaw L., Parker R.J., et al. Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect 98 (1992) 53-59
127. Reed E., Parker R.J., Gill I., et al. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 53 (1993) 3694-3699
128. Motzer R.J., Reed E., Perera F., et al. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 73 (1994) 2843-2852
129. Poirier M.C., Reed E., Shamkhani H., Tarone R.E., and Gupta-Burt S. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect 99 (1993) 149-154
130. Meijera C., van Luyn M.J., Nienhuis E.F., Blom N., Mulder N.H., and de Vries E.G. Ultrastructural morphology and localisation of cisplatin-induced platinum-DNA adducts in a cisplatin-sensitive and -resistant human small cell lung cancer cell line using electron microscopy. Biochem Pharmacol 61 (2001) 573-578
131. Shirazi F. Cell cycle dependency of cisplatin cytotoxicity on ovarian cancer cells. PhD Thesis, Department of Cellular and Molecular Medicine. Ottawa, Canada: University of Ottawa; 1998.
132. Abbosh P.H., Montgomery J.S., Starkey J.A., et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66 (2006) 5582-5591
133. Kuin A., Aalders M., Lamfers M., et al. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Br J Cancer 79 (1999) 793-801
134. Murakami T., Shibuya I., Ise T., et al. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int J Cancer 93 (2001) 869-874
135. Luciani F., Spada M., De Milito A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 96 (2004) 1702-1713
136. + channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance. Anticancer Res 25 (2005) 4113-4122
137. Wahl M.L., Owen J.A., Burd R., et al. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1 (2002) 617-628
138. Webb S.D., Sherratt J.A., and Fish R.G. Mathematical modelling of tumour acidity: regulation of intracellular pH. J Theor Biol 196 (1999) 237-250
139. Stubbs M., McSheehy P.M., and Griffiths J.R. Causes and consequences of acidic pH in tumors: a magnetic resonance study. Adv Enzyme Regul 39 (1999) 13-30
140. Newell K., Franchi A., Pouyssegur J., and Tannock I. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 90 (1993) 1127-1131
141. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89 (2003) 877-885
142. de Graaf T.W., de Jong S., de Vries E.G., and Mulder N.H. Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer. Anticancer Res 17 (1997) 369-375
143. Albain K.S., Crowley J.J., Hutchins L., et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Groxup Study 8605 report and analysis of recurrent disease data base. Cancer 72 (1993) 1184-1191
144. Lassen U., Kristjansen P.E., Osterlind K., et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 7 (1996) 365-371
145. Kawahara M., Fukuoka M., Saijo N., et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 27 (1997) 158-165
146. Hong R.L., Ting L.L., Ko J.Y., et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19 (2001) 4305-4313
147. Keilholz U., Martus P., Punt C.J., et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 38 (2002) 1501-1511
148. Guida M., Ravaioli A., Sileni V.C., et al. Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. J Transl Med 1 (2003) 13
149. Polee M.B., Hop W.C., Kok T.C., et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 89 (2003) 2045-2050
150. O'Connell J.P., Kris M.G., Gralla R.J., et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4 (1986) 1604-1614
151. Shinkai T., Eguchi K., Sasaki Y., et al. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer 27 (1991) 571-575
152. Albain K.S., Crowley J.J., LeBlanc M., and Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9 (1991) 1618-1626
153. Takifuji N., Fukuoka M., Negoro S., et al. Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy. Gan To Kagaku Ryoho 17 (1990) 429-434
154. Carles J., Rosell R., Ariza A., et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 10 (1993) 209-219
155. Gregorc V., Darwish S., Ludovini V., et al. The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. Lung Cancer 42 (2003) 275-281
156. Kawahara M., Furuse K., Kodama N., et al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 68 (1991) 714-719
157. Borges M., Sculier J.P., Paesmans M., et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC). Lung Cancer 16 (1996) 21-33
158. Ray P., Quantin X., Grenier J., and Pujol J.L. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev 22 (1998) 293-304
159. Yoo B.C., Ku J.L., Hong S.H., et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 108 (2004) 532-539
160. Koberle B., Grimaldi K.A., Sunters A., Hartley J.A., Kelland L.R., and Masters J.R. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70 (1997) 551-555
161. Dempke W., Voigt W., Grothey A., and Schmoll H.J. Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. Anticancer Drugs 10 (1999) 545-549
162. Zhen W., Link Jr. C.J., O'Connor P.M., et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12 (1992) 3689-3698
163. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24 (1998) 331-344
164. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
165. Yu J.J., Bicher A., Ma Y.K., Bostick-Bruton F., and Reed E. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues. Cancer Lett 151 (2000) 127-132
166. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., and Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84 (1992) 1512-1517
167. Rosell R., Taron M., Barnadas A., Scagliotti G., Sarries C., and Roig B. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 10 (2003) 297-305
168. Kang S., Ju W., Kim J.W., et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38 (2006) 320-324
169. Rosell R., Taron M., Ariza A., et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31 (2004) 20-27
170. Camps C., Sarries C., Roig B., et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 4 (2003) 237-241
171. States J.C., and Reed E. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Lett 108 (1996) 233-237
172. D'Andrea A.D. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2 (2003) 290-292
173. Olopade O.I., and Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3 (2003) 417-420
174. Trenz K., Lugowski S., Jahrsdorfer U., Jainta S., Vogel W., and Speit G. Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. Mutat Res 544 (2003) 279-288
175. Raaphorst G.P., Yang D.P., Grewaal D., Stewart D., Goel R., and Ng C.E. Analysis of mechanisms of cisplatin resistance in three pairs of human tumour cell lines expressing normal and resistant responses to cisplatin. Oncol Rep 2 (1995) 1037-1043
176. Bergoglio V., Canitrot Y., Hogarth L., et al. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene 20 (2001) 6181-6187
177. Bassett E., Vaisman A., Havener J.M., Masutani C., Hanaoka F., and Chaney S.G. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro. Biochemistry 42 (2003) 14197-14206
178. Raaphorst G.P., Cybulski S.E., Sobol R., and Ng C.E. The response of human breast tumour cell lines with altered polymerase beta levels to cisplatin and radiation. Anticancer Res 21 (2001) 2079-2083
179. Albertella M.R., Lau A., and O'Connor M.J. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst) 4 (2005) 583-593
180. Boudsocq F., Benaim P., Canitrot Y., et al. Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol Pharmacol 67 (2005) 1485-1492
181. Raaphorst G.P., Ng C.E., and Yang D.P. Comparison of response to radiation, hyperthermia and cisplatin in parental and polymerase beta knockout cells. Int J Hyperthermia 18 (2002) 33-39
182. Dempke W., Voigt W., Grothey A., Hill B.T., and Schmoll H.J. Cisplatin resistance and oncogenes-a review. Anticancer Drugs 11 (2000) 225-236
183. Wu F., Lin X., Okuda T., and Howell S.B. DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res 64 (2004) 8029-8035
184. Lin X., Trang J., Okuda T., and Howell S.B. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res 12 (2006) 563-568
185. Albertella M.R., Green C.M., Lehmann A.R., and O'Connor M.J. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 65 (2005) 9799-9806
186. Chaney S.G., Campbell S.L., Bassett E., and Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53 (2005) 3-11
187. Lin X., Okuda T., Trang J., and Howell S.B. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 69 (2006) 1748-1754
188. Jiang H.Y., Hickey R.J., Abdel-Aziz W., and Malkas L.H. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome. Cancer Chemother Pharmacol 45 (2000) 320-328
189. Yoshida S., Yamada M., and Masaki S. Inhibition of DNA polymerase-alpha and -beta of calf thymus by 1-beta-d-arabinofuranosylcytosine-5′-triphosphate. Biochim Biophys Acta 477 (1977) 144-150
190. Bergerat J.P., Drewinko B., Corry P., Barlogie B., and Ho D.H. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-d-arabinofuranosylcytosine. Cancer Res 41 (1981) 25-30
191. Ali-Osman F., Berger M.S., Rajagopal S., Spence A., and Livingston R.B. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 53 (1993) 5663-5668
192. Xu Z.Y., Loignon M., Han F.Y., Panasci L., and Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314 (2005) 495-505
193. Britten R.A., Kuny S., and Perdue S. Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. Br J Cancer 79 (1999) 843-849
194. Nagatani G., Nomoto M., Takano H., et al. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res 61 (2001) 1592-1597
195. Sun C.L., and Chao C.C. Cross-resistance to death ligand-induced apoptosis in cisplatin-selected HeLa cells associated with overexpression of DDB2 and subsequent induction of cFLIP. Mol Pharmacol 67 (2005) 1307-1314
196. Pepponi R., Marra G., Fuggetta M.P., et al. The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304 (2003) 661-668
197. Passagne I., Evrard A., Depeille P., Cuq P., Cupissol D., and Vian L. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 211 (2006) 97-105
198. Olivero O.A., Chang P.K., Lopez-Larraza D.M., Semino-Mora M.C., and Poirier M.C. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 391 (1997) 79-86
199. Berry S., and Kinsella T.J. Targeting DNA mismatch repair for radiosensitization. Semin Radiat Oncol 11 (2001) 300-315
200. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56 (1996) 3087-3090
201. Fink D., Zheng H., Nebel S., et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57 (1997) 1841-1845
202. Lage H., Christmann M., Kern M.A., et al. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 80 (1999) 744-750
203. Lin X., and Howell S.B. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Mol Pharmacol 56 (1999) 390-395
204. Ercoli A., Ferrandina G., Genuardi M., et al. Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer. Int J Gynecol Cancer 15 (2005) 308-311
205. Ono Y., Nonomura N., Harada Y., et al. Loss of p73 induction in a cisplatin-resistant bladder cancer cell line. Mol Urol 5 (2001) 25-30
206. Lin X., and Howell S.B. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 5 (2006) 1239-1247
207. Olasz J., Mandoky L., Geczi L., Bodrogi I., Csuka O., and Bak M. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors. Anticancer Res 25 (2005) 4319-4324
208. Richardson A., and Kaye S.B. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 8 (2005) 311-321
209. Gonzalez V.M., Fuertes M.A., Alonso C., and Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 59 (2001) 657-663
210. Minagawa Y., Kigawa J., Itamochi H., et al. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn J Cancer Res 90 (1999) 1373-1379
211. Mori T., Okamoto H., Takahashi N., Ueda R., and Okamoto T. Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett 465 (2000) 124-128
212. Asada N., Tsuchiya H., and Tomita K. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Res 19 (1999) 5131-5137
213. Kigawa J., Sato S., Shimada M., et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 14 (2001) 165-171
214. Perego P., Giarola M., Righetti S.C., et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56 (1996) 556-562
215. Mandic R., Schamberger C.J., Muller J.F., et al. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 11 (2005) 6845-6852
216. Houldsworth J., Xiao H., Murty V.V., et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16 (1998) 2345-2349
217. Bradford C.R., Zhu S., Poore J., et al., Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. p53 Mutation as a prognostic marker in advanced laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 123 (1997) 605-609
218. Wang W., Rastinejad F., and El-Deiry W.S. Restoring p53-dependent tumor suppression. Cancer Biol Ther 2 (2003) S55-S63
219. Nakayama K., Takebayashi Y., Nakayama S., et al. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 192 (2003) 227-235
220. Kawasaki M., Nakanishi Y., Yatsunami J., et al. p53 Immunostaining predicts chemosensitivity in non-small cell lung cancer: a preliminary report. Cancer J Sci Am 2 (1996) 217-220
221. Datta K., Shah P., Srivastava T., Mathur S.G., Chattopadhyay P., and Sinha S. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cancer Gene Ther 11 (2004) 525-531
222. Achanzar W.E., Webber M.M., and Waalkes M.P. Altered apoptotic gene expression and acquired apoptotic resistance in cadmium-transformed human prostate epithelial cells. Prostate 52 (2002) 236-244
223. Toyozumi Y., Arima N., Izumaru S., Kato S., Morimatsu M., and Nakashima T. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells. Int J Oncol 25 (2004) 721-728
224. Spierings D.C., de Vries E.G., Vellenga E., and de Jong S. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Cell Death Differ 10 (2003) 808-822
225. Kuwahara D., Tsutsumi K., Kobayashi T., Hyoudou M., and Koizuka I. Inhibition of caspase-9 activity in cisplatin-resistant head and neck squamous cell carcinoma. Nippon Jibiinkoka Gakkai Kaiho 105 (2002) 152-157
226. Isonishi S., Saitou M., Yasuda M., and Tanaka T. Mitochondria in platinum resistant cells. Hum Cell 14 (2001) 203-210
227. Cheng J.Q., Jiang X., Fraser M., et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 5 (2002) 131-146
228. Nomura T., Yamasaki M., Nomura Y., and Mimata H. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 14 (2005) 993-997
229. Yang X., Xing H., Gao Q., et al. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 97 (2005) 413-421
230. Amantana A., London C.A., Iversen P.L., and Devi G.R. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3 (2004) 699-707
231. Konishi T., Sasaki S., Watanabe T., Kitayama J., and Nagawa H. Exogenous expression of hRFI induces multidrug resistance through escape from apoptosis in colorectal cancer cells. Anticancer Res 25 (2005) 2737-2741
232. Wang Z., Xie Y., and Wang H. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther 4 (2005) 716-719
233. Sharma H., Sen S., Lo Muzio L., Mariggio A., and Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 4 (2005) 720-727
234. Beale P.J., Rogers P., Boxall F., Sharp S.Y., and Kelland L.R. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 82 (2000) 436-440
235. Yu L., and Wang Z. Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. J Huazhong Univ Sci Technol Med Sci 24 (2004) 151-153
236. Dong Z., and Wang J. Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem 279 (2004) 9215-9221
237. Williams J., Lucas P.C., Griffith K.A., et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96 (2005) 287-295
238. Yang X., Zheng F., Xing H., et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 130 (2004) 423-428
239. Raspollini M.R., Castiglione F., Degl'Innocenti D.R., et al. Bcl-2 in ovarian carcinoma: a clinicopathologic, immunohistochemical and molecular study. Pathologica 96 (2004) 465-469
240. Chanvorachote P., Nimmannit U., Stehlik C., et al. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res 66 (2006) 6353-6360
241. Shi Y., Zhai H., Wang X., et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. Exp Cell Res 296 (2004) 337-346
242. Kim J.K., Kim K.D., Lee E., et al. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 212 (2004) 61-70
243. Abedini M.R., Qiu Q., Yan X., and Tsang B.K. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23 (2004) 6997-7004
244. Mercer S.J., Di Nicolantonio F., Knight L.A., et al. Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. Anticancer Drugs 16 (2005) 495-500
245. Mizutani Y., Nakanishi H., Li Y.N., Sato N., Kawauchi A., and Miki T. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J Urol 172 (2004) 1474-1479
246. Sugiura T., Saikawa Y., Kubota T., et al. Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo 17 (2003) 229-233
247. Czembirek C., Eder-Czembirek C., Erovic B.M., Turhani D., Selzer E., and Thurnher D. Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines. Oncol Rep 14 (2005) 1523-1526
248. Xi H., Baldus S.E., Warnecke-Eberz U., et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11 (2005) 8341-8347
249. Takatori H., Natsugoe S., Okumura H., et al. Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep 13 (2005) 697-701
250. Wulfing C., Eltze E., Von Struensee D., et al. Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications. Aktuelle Urol 35 (2004) 331-338
251. Distefano M., Ferrandina G., Smaniotto D., et al. Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology 67 (2004) 103-111
252. Ferrandina G., Lauriola L., Distefano M.G., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20 (2002) 973-981
253. Ferrandina G., Lauriola L., Zannoni G.F., et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13 (2002) 1205-1211
254. Rosell R., Scagliotti G., Danenberg K.D., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22 (2003) 3548-3553
255. Fortin A., Raybaud-Diogene H., Tetu B., Deschenes R., Huot J., and Landry J. Overexpression of the 27 KDa heat shock protein is associated with thermoresistance and chemoresistance but not with radioresistance. Int J Radiat Oncol Biol Phys 46 (2000) 1259-1266
256. Yamamoto K., Okamoto A., Isonishi S., Ochiai K., and Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 168 (2001) 173-181
257. Garrido C., Ottavi P., Fromentin A., et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 57 (1997) 2661-2667
258. Richards E.H., Hickey E., Weber L., and Master J.R. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56 (1996) 2446-2451
259. Zacal N., Espiritu M., Singh G., and Rainbow A.J. Increased BNip3 and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29 cells. Biochem Biophys Res Commun 331 (2005) 648-657
260. Yang W.L., Yang-Biggs G., Wu Y., et al. Development of cross-resistance between heat and cisplatin or hydroxyurea treatments in FaDu squamous carcinoma cells. J Surg Res 111 (2003) 143-151
261. Huang C., Zhou C., and Zhao M. The effect of antisense hsp90 beta on the malignant phenotype and sensitivity of HeLa cells to chemotherapeutic drugs. Zhonghua Zhong Liu Za Zhi 22 (2000) 14-16
262. Brozovic A., Simaga S., and Osmak M. Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia. Neoplasma 48 (2001) 99-103
263. Belfi C.A., Chatterjee S., Gosky D.M., Berger S.J., and Berger N.A. Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation. Biochem Biophys Res Commun 257 (1999) 361-368
264. Kohno K., Uchiumi T., Niina I., et al. Transcription factors and drug resistance. Eur J Cancer 41 (2005) 2577-2586
265. Fricke E., Hermannstadter C., Keller G., et al. Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide, and 5-fluorouracil. Oncology 66 (2004) 150-159
266. Witta S.E., Gemmill R.M., Hirsch F.R., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66 (2006) 944-950
267. Liang X.J., Shen D.W., and Gottesman M.M. Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. Mol Pharmacol 65 (2004) 1217-1224
268. Bai L., Zhu R., Chen Z., et al. Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. Biochem Pharmacol 71 (2006) 1265-1271
269. Hsu C.H., Gao M., Chen C.L., Yeh P.Y., and Cheng A.L. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology 68 (2005) 538-547
270. Goswami S., Wang W., Wyckoff J.B., and Condeelis J.S. Breast cancer cells isolated by chemotaxis from primary tumors show increased survival and resistance to chemotherapy. Cancer Res 64 (2004) 7664-7667
271. Menendez J.A., Mehmi I., and Lupu R. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Int J Oncol 26 (2005) 649-659
272. Menendez J.A., Mehmi I., and Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24 (2006) 3735-3746
273. Boudny V., Murakami Y., Nakano S., and Niho Y. Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells. Anticancer Res 19 (1999) 5203-5206
274. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
275. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
276. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
277. Davies A.M., Ho C., Lara Jr. P.N., Mack P., Gumerlock P.H., and Gandara D.R. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 7 (2006) 385-388
278. Lee S., Choi E.J., Jin C., and Kim D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97 (2005) 26-34
279. Ohta T., Ohmichi M., Hayasaka T., et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147 (2006) 1761-1769
280. Hovelmann S., Beckers T.L., and Schmidt M. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Br J Cancer 90 (2004) 2370-2377
281. Gagnon V., Mathieu I., Sexton E., Leblanc K., and Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94 (2004) 785-795
282. Mondesire W.H., Jian W., Zhang H., et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10 (2004) 7031-7042
283. 2+ signaling and cisplatin resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 132 (2006) 19-24
284. Wang S.J., and Bourguignon L.Y. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 132 (2006) 771-778
285. Tsunoda T., Koga H., Yokomizo A., et al. Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 24 (2005) 1396-1402
286. Schenk P.W., Stoop H., Bokemeyer C., et al. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia 6 (2004) 297-301
287. Isonishi S., Hom D.K., Thiebaut F.B., et al. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 51 (1991) 5903-5909
288. Hamamoto T., Suzuki K., Sasaki H., Ichikawa M., Kodama S., and Watanabe M. Differences in effects of oncogenes on sensitivity to anticancer drugs. J Radiat Res (Tokyo) 46 (2005) 197-203
289. Youn C.K., Kim M.H., Cho H.J., et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 64 (2004) 4849-4857
290. Brozovic A., Fritz G., Christmann M., et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112 (2004) 974-985
291. Pan B., Yao K.S., Monia B.P., et al. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 63 (2002) 1699-1707
292. Li F., Meng L., Zhou J., et al. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1. Biochem Biophys Res Commun 335 (2005) 1070-1077
293. Roberts D., Schick J., Conway S., et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92 (2005) 1149-1158
294. Kato K., Nomoto M., Izumi H., et al. functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells. Biochim Biophys Acta 1493 (2000) 91-100
295. Ikuta K., Takemura K., Kihara M., et al. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol Rep 13 (2005) 217-222
296. Belenkov A.I., Shenouda G., Rizhevskaya E., et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3 (2004) 1525-1532
297. Righetti S.C., Perego P., Carenini N., et al. Molecular alterations of cells resistant to platinum drugs: role of PKCalpha. Biochim Biophys Acta 1763 (2006) 93-100
298. Baldwin R.M., Garratt-Lalonde M., Parolin D.A., Krzyzanowski P.M., Andrade M.A., and Lorimer I.A. Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. Oncogene 25 (2006) 2909-2919
299. Olivero M., Ruggiero T., Saviozzi S., et al. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Mol Cancer Ther 5 (2006) 1126-1135
300. Cohen P.T., Philp A., and Vazquez-Martin C. Protein phosphatase 4-from obscurity to vital functions. FEBS Lett 579 (2005) 3278-3286
301. Burger H., Capello A., Schenk P.W., Stoter G., Brouwer J., and Nooter K. A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin. Biochem Biophys Res Commun 269 (2000) 767-774
302. Ishii T., Matsuse T., Masuda M., and Teramoto S. The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells. Exp Lung Res 30 (2004) 687-703
303. Biliran Jr. H., Wang Y., Banerjee S., et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 11 (2005) 6075-6086
304. Matsumura Y., Yamagishi N., Miyakoshi J., Imamura S., and Takebe H. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett 115 (1997) 91-96
305. Zhang P., Gao W., Li H., Reed E., and Chen F. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun 328 (2005) 567-572
306. Carrassa L., Broggini M., Erba E., and Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 3 (2004) 1177-1181
307. Du Y., Yin F., Liu C., et al. Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway. Biochem Biophys Res Commun 345 (2006) 1092-1098
308. Amaya K., Ohta T., Kitagawa H., et al. II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 25 (2004) 849-856
309. Eichholtz-Wirth H., and Sagan D. IkappaB/NF-kappaB mediated cisplatin resistance in HeLa cells after low-dose gamma-irradiation is associated with altered SODD expression. Apoptosis 5 (2000) 255-263
310. Mohammad R.M., Banerjee S., Li Y., Aboukameel A., Kucuk O., and Sarkar F.H. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 106 (2006) 1260-1268
311. Venkatraman M., Anto R.J., Nair A., Varghese M., and Karunagaran D. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinogen 44 (2005) 51-59
312. Sharma V., Peddibhotla S., and Tepe J.J. Sensitization of cancer cells to DNA damaging agents by imidazolines. J Am Chem Soc 128 (2006) 9137-9143
313. Ruan H.Y., Masuda M., Ito A., et al. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. Head Neck 28 (2006) 158-165
314. Poma P., Notarbartolo M., Labbozzetta M., et al. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol 28 (2006) 923-930
315. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65 (2005) 6934-6942
316. Lee C.T., Seol J.Y., Lee S.Y., et al. The effect of adenovirus-IkappaBalpha transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diamminedichloroplatinum(II)(cisplatin) and doxorubicin(adriamycin). Lung Cancer 41 (2003) 199-206
317. Weaver K.D., Yeyeodu S., Cusack Jr. J.C., Baldwin Jr. A.S., and Ewend M.G. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61 (2003) 187-196
318. Mabuchi S., Ohmichi M., Nishio Y., et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279 (2004) 23477-23485
319. Notarbartolo M., Poma P., Perri D., Dusonchet L., Cervello M., and D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 224 (2005) 53-65
320. Lu Y.S., Yeh P.Y., Chuang S.E., Gao M., Kuo M.L., and Cheng A.L. Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. J Endocrinol 188 (2006) 311-319
321. Abdel-Latif M.M., Raouf A.A., Sabra K., Kelleher D., Reynolds J.V., and Vitamin. C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother 17 (2005) 539-549
322. Zhong X., Li X., Wang G., et al. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol 25 (2004) 445-451
323. Strozyk E., Poppelmann B., Schwarz T., and Kulms D. Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene 25 (2006) 6239-6251
324. Kim S.B., Kim J.S., Lee J.H., et al. NF-kappaB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells. FEBS Lett 580 (2006) 311-318
325. Shehata M., Shehata M., Shehata F., and Pater A. Apoptosis effects of Xrel3 c-Rel/Nuclear Factor-kappa B homolog in human cervical cancer cells. Cell Biol Int 29 (2005) 429-440
326. Torigoe T., Izumi H., Ishiguchi H., et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5 (2005) 15-27
327. Wilson L.A., Yamamoto H., and Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther 3 (2004) 823-832
328. Furuchi T., Ishikawa H., Miura N., et al. Two nuclear proteins, Cin5 and Ydr259c, confer resistance to cisplatin in Saccharomyces cerevisiae. Mol Pharmacol 59 (2001) 470-474
329. Yahata H., Kobayashi H., Kamura T., et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 128 (2002) 621-626
330. Perry III W.L., Shepard R.L., Sampath J., et al. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed-a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res 65 (2005) 6593-6600
331. Sakamoto M., Umayahara K., Sakamoto H., et al. Cancer-associated gene abnormalities and chemosensitivity. Gan To Kagaku Ryoho 25 (1998) 1819-1831
332. Takano M., Kudo K., Goto T., Yamamoto K., Kita T., and Kikuchi Y. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell 14 (2001) 267-271
333. Osterberg L., Levan K., Partheen K., Helou K., and Horvath G. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet 163 (2005) 144-150
334. Nessling M., Kern M.A., Schadendorf D., and Lichter P. Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines. Cytogenet Cell Genet 87 (1999) 286-290
335. Hiorns L.R., Seckl M.J., Paradinas F., et al. A molecular cytogenetic approach to studying platinum resistance. J Inorg Biochem 77 (1999) 95-104
336. Rao P.H., Houldsworth J., Palanisamy N., et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 58 (1998) 4260-4263
337. Leyland-Jones B., Kelland L.R., Harrap K.R., and Hiorns L.R. Genomic imbalances associated with acquired resistance to platinum analogues. Am J Pathol 155 (1999) 77-84
338. Wasenius V.M., Jekunen A., Monni O., et al. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer 18 (1997) 286-291
339. Kiyozuka Y., Yamamoto D., Yang J., et al. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells. Anticancer Res 20 (2000) 203-212
340. Makhija S., Sit A., Edwards R., et al. Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol Oncol 90 (2003) 3-9
341. Harper M.E., Antoniou A., Villalobos-Menuey E., et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. Faseb J 16 (2002) 1550-1557
342. Yoon S.J., Park I., Kwak C., and Lee E. Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells. Oncol Rep 10 (2003) 1363-1367
343. Tregubova N.A., Iurchenko O.V., Todor I.N., Sudiakov V.S., Kulik G.I., and Chekhun V.F. Ultrastructural organization of carcinoma Lewis (3LL) cells during cisplatin resistance formation. Tsitol Genet 40 (2006) 58-65
344. Peters D., Freund J., and Ochs R.L. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 4 (2005) 1605-1616
345. Helleman J., Jansen M.P., Span P.N., et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118 (2006) 1963-1971
346. Castagna A., Antonioli P., Astner H., et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4 (2004) 3246-3267